IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Confirmation No.: 3998

MADGE et al. Art Unit: 1614

Appl. No.: 10/658,971 Examiner: KWON, Brian Yong S.

Filed: September 9, 2003 Atty. Docket: 2451.0090008/BJD/GER

For: Boronic Acid Salts Useful in

Parenteral Formulations

Ninth Supplemental Information Disclosure Statement Under 37 C.F.R. § 1.97(b)

Mail Stop Amendment

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

Listed on this Ninth Supplemental Information Disclosure Statement are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. This Ninth Supplemental Information Disclosure Statement is a continuation of the Applicants' Eighth Information Disclosure Statement filed on April 19, 2007, in connection with the above-captioned application.

The Examiner's attention is directed to the following co-pending U.S. Patent Applications, which are directed to related technical subject matter:

Application No. 10/591,962, inventors Patrick, G.M., et al., filed September 8, 2006; and

Application No. 10/592,265, inventors Combe-Marzelle, S.M., et al., filed March 9, 2005.

The identification of these U.S. Patent Applications is not to be construed as a waiver of secrecy as to those applications now or upon issuance of the present application as a patent. The Examiner is respectfully requested to consider the cited applications and the art cited therein during examination.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached IDS Forms based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed before the mailing of a first Office Action after the filing of a request for continued examination under 37 C.F.R. § 1.114. No statement or fee is required.

It is respectfully requested that the Examiner indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Grant E. Reed

Attorney for Applicants Registration No. 41,264

Date: August 7, 2007

1100 New York Avenue, N.W. Washington, D.C. 20005-3934 (202) 371-2600

705910_1